MannKind Corporation MNKD
4.23 USD +0.04 (+0.95%)
At closeNov 10, 2026, 4:00 PM EST
4.23 0.00 0.00%
After hours · Nov 10, 4:00 PM ET
4.07 Day range 4.29
2.23 52-week range 6.51
- YTD
- -25.40%
- 1 year
- -21.96%
News
benzinga.com RBC Capital Maintains Sector Perform on MannKind, Raises Price Target to $5 RBC Capital analyst Douglas Miehm maintains MannKind (NASDAQ:MNKD) with a Sector Perform and raises the price target from $4.75 to $5.- benzinga.com Cantor Fitzgerald Maintains Overweight on MannKind, Raises Price Target to $10 Cantor Fitzgerald analyst Olivia Brayer Saunders maintains MannKind (NASDAQ:MNKD) with a Overweight and raises the price target from $8 to $10.
seekingalpha.com MannKind Corporation (MNKD) Q3 2026 Earnings Call Transcript MannKind Corporation (MNKD) Q3 2026 Earnings Call Transcript
defenseworld.net MannKind Q3 Earnings Call Highlights MannKind (NASDAQ: MNKD) expects to return to profitability in the fourth quarter after reporting higher third-quarter revenue and a net loss, as the company's FUROSCIX ReadyFlow and pediatric Afrezza…
marketbeat.com MannKind Q3 Earnings Call Highlights MannKind NASDAQ: MNKD expects to return to profitability in the fourth quarter after reporting higher third-quarter revenue and a net loss, as the company's FUROSCIX ReadyFlow and pediatric Afrezza…
zacks.com Compared to Estimates, MannKind (MNKD) Q3 Earnings: A Look at Key Metrics Although the revenue and EPS for MannKind (MNKD) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall…
zacks.com MannKind (MNKD) Reports Q3 Loss, Misses Revenue Estimates MannKind (MNKD) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to earnings of $0.03 per share a year ago.
benzinga.com Cantor Fitzgerald Reiterates Overweight on MannKind, Maintains $8 Price Target Cantor Fitzgerald analyst Olivia Brayer Saunders reiterates MannKind (NASDAQ:MNKD) with a Overweight and maintains $8 price target.
benzinga.com This MannKind Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday Analysts initiate coverage: RSI Equal-Weight ($22), NWCL Neutral, HDRN Buy.
benzinga.com Chardan Capital Initiates Coverage On MannKind with Buy Rating, Announces Price Target of $10 Chardan Capital analyst Andreas Argyrides initiates coverage on MannKind (NASDAQ:MNKD) with a Buy rating and announces Price Target of $10.
benzinga.com Reported Friday, MannKind’s Under-10-Second Furoscix ReadyFlow Autoinjector Shows Urine Output Comparable To IV Furosemide In New HFSA 2026 Analyses, Supporting Outpatient Edema Management In Heart Failure And CKD New analyses on Furoscix ReadyFlow PK/PD performance delivered via an autoinjector demonstrated comparable urine output to IV furosemideConsistent bioavailability, diuresis and natriuresis across…